Benzodiazepine withdrawal in older people: what is the prevalence, what are the signs, and which patients?
Purpose Benzodiazepines (BZDs) and related drugs (Z-drugs) are mainly taken chronically, and older people are much more likely to take them on a chronic basis despite recommendations. Withdrawal symptoms could be an obstacle to stopping BZD/Z-drug administration. The main objective of this study is...
Gespeichert in:
| Veröffentlicht in: | European journal of clinical pharmacology 2021-02, Vol.77 (2), p.171-177 |
|---|---|
| Hauptverfasser: | , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 177 |
|---|---|
| container_issue | 2 |
| container_start_page | 171 |
| container_title | European journal of clinical pharmacology |
| container_volume | 77 |
| creator | Jobert, Alexandra Laforgue, Edouard-Jules Grall-Bronnec, Marie Rousselet, Morgane Péré, Morgane Jolliet, Pascale Feuillet, Fanny Victorri-Vigneau, Caroline |
| description | Purpose
Benzodiazepines (BZDs) and related drugs (Z-drugs) are mainly taken chronically, and older people are much more likely to take them on a chronic basis despite recommendations. Withdrawal symptoms could be an obstacle to stopping BZD/Z-drug administration. The main objective of this study is to estimate the prevalence of withdrawal symptoms in patients aged 65 years and older who have experience a stop of BZD/Z-drug. The secondary objectives are to describe the withdrawal symptoms and identify factors associated.
Method
This ancillary study was based on a national observational study in patients with chronic BZD/Z-drug consumption. Patients who made at least one BZD/Z-drug stop experience were selected. Withdrawal symptoms are described, and a logistic regression was carried out to identify the variables most associated with withdrawal symptoms.
Results
In total, 697 patients were selected: 78% experienced at least one withdrawal symptom after a stop administering BZDs or Z-drugs; most of the withdrawal symptoms were psychological disorders.
Conclusion
Our study identifies a specific population experiencing withdrawal symptoms and who cannot stop administering BZD/Z-drug. We assume that withdrawal symptoms in patients with chronic use play an essential role in the nonstop use of BZD/Z-drugs. |
| doi_str_mv | 10.1007/s00228-020-03007-7 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_hal_p</sourceid><recordid>TN_cdi_hal_primary_oai_HAL_hal_03244134v1</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2448403228</sourcerecordid><originalsourceid>FETCH-LOGICAL-c409t-d3b9baacfd99c51290309dc0b43243a4298cde61a1cd570b46ce8452047b33493</originalsourceid><addsrcrecordid>eNp9kU9r3DAQxUVpaLZpvkAPRdBLCnE7-rO2lUtIQ5sEFnppz0KWZmMtXtmRvLs0n77aOEkhh5wG3vzmzQyPkI8MvjKA6lsC4LwugEMBIgtF9YbMmBS8YCDZWzIDEKwoVQWH5H1KKwA2VyDekUOR8bLk5YysvmO475039zj4gHTnx9ZFszMd9YH2ncNIB-yHDs_orjUj9YmOLdIh4tZ0GCyeTrqJ-NBI_jakU2qCy7q3LR3M6DGM6fwDOViaLuHxYz0if37--H15XSx-Xd1cXiwKK0GNhRONaoyxS6eUnTOeLwblLDT5MSmM5Kq2DktmmHXzKsulxVrOOciqEUIqcUS-TL6t6fQQ_drEv7o3Xl9fLPReg2wkmZBbltmTiR1if7fBNOq1Txa7zgTsN0lnsJaZ53VGP79AV_0mhvxJpqoKFDCoMsUnysY-pYjL5wsY6H1qekpN59T0Q2p6P_Tp0XrTrNE9jzzFlAExASm3wi3G_7tfsf0Hz8ugRw</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2477090107</pqid></control><display><type>article</type><title>Benzodiazepine withdrawal in older people: what is the prevalence, what are the signs, and which patients?</title><source>SpringerLink Journals</source><creator>Jobert, Alexandra ; Laforgue, Edouard-Jules ; Grall-Bronnec, Marie ; Rousselet, Morgane ; Péré, Morgane ; Jolliet, Pascale ; Feuillet, Fanny ; Victorri-Vigneau, Caroline</creator><creatorcontrib>Jobert, Alexandra ; Laforgue, Edouard-Jules ; Grall-Bronnec, Marie ; Rousselet, Morgane ; Péré, Morgane ; Jolliet, Pascale ; Feuillet, Fanny ; Victorri-Vigneau, Caroline ; FAN-Network</creatorcontrib><description>Purpose
Benzodiazepines (BZDs) and related drugs (Z-drugs) are mainly taken chronically, and older people are much more likely to take them on a chronic basis despite recommendations. Withdrawal symptoms could be an obstacle to stopping BZD/Z-drug administration. The main objective of this study is to estimate the prevalence of withdrawal symptoms in patients aged 65 years and older who have experience a stop of BZD/Z-drug. The secondary objectives are to describe the withdrawal symptoms and identify factors associated.
Method
This ancillary study was based on a national observational study in patients with chronic BZD/Z-drug consumption. Patients who made at least one BZD/Z-drug stop experience were selected. Withdrawal symptoms are described, and a logistic regression was carried out to identify the variables most associated with withdrawal symptoms.
Results
In total, 697 patients were selected: 78% experienced at least one withdrawal symptom after a stop administering BZDs or Z-drugs; most of the withdrawal symptoms were psychological disorders.
Conclusion
Our study identifies a specific population experiencing withdrawal symptoms and who cannot stop administering BZD/Z-drug. We assume that withdrawal symptoms in patients with chronic use play an essential role in the nonstop use of BZD/Z-drugs.</description><identifier>ISSN: 0031-6970</identifier><identifier>EISSN: 1432-1041</identifier><identifier>DOI: 10.1007/s00228-020-03007-7</identifier><identifier>PMID: 33006626</identifier><language>eng</language><publisher>Berlin/Heidelberg: Springer Berlin Heidelberg</publisher><subject>Antidepressants ; Benzodiazepines ; Biomedical and Life Sciences ; Biomedicine ; Clinical Trial ; Drug withdrawal ; Drugs ; Life Sciences ; Older people ; Pharmacology/Toxicology ; Population studies ; Withdrawal</subject><ispartof>European journal of clinical pharmacology, 2021-02, Vol.77 (2), p.171-177</ispartof><rights>Springer-Verlag GmbH Germany, part of Springer Nature 2020</rights><rights>Springer-Verlag GmbH Germany, part of Springer Nature 2020.</rights><rights>Distributed under a Creative Commons Attribution 4.0 International License</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c409t-d3b9baacfd99c51290309dc0b43243a4298cde61a1cd570b46ce8452047b33493</citedby><cites>FETCH-LOGICAL-c409t-d3b9baacfd99c51290309dc0b43243a4298cde61a1cd570b46ce8452047b33493</cites><orcidid>0000-0001-9117-0934 ; 0000-0003-0722-7243 ; 0000-0003-0191-9249 ; 0000-0002-7400-1212 ; 0000-0002-3745-2532 ; 0000-0001-5804-5269 ; 0000-0003-4027-7963</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s00228-020-03007-7$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s00228-020-03007-7$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>230,314,777,781,882,27905,27906,41469,42538,51300</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/33006626$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink><backlink>$$Uhttps://hal.science/hal-03244134$$DView record in HAL$$Hfree_for_read</backlink></links><search><creatorcontrib>Jobert, Alexandra</creatorcontrib><creatorcontrib>Laforgue, Edouard-Jules</creatorcontrib><creatorcontrib>Grall-Bronnec, Marie</creatorcontrib><creatorcontrib>Rousselet, Morgane</creatorcontrib><creatorcontrib>Péré, Morgane</creatorcontrib><creatorcontrib>Jolliet, Pascale</creatorcontrib><creatorcontrib>Feuillet, Fanny</creatorcontrib><creatorcontrib>Victorri-Vigneau, Caroline</creatorcontrib><creatorcontrib>FAN-Network</creatorcontrib><title>Benzodiazepine withdrawal in older people: what is the prevalence, what are the signs, and which patients?</title><title>European journal of clinical pharmacology</title><addtitle>Eur J Clin Pharmacol</addtitle><addtitle>Eur J Clin Pharmacol</addtitle><description>Purpose
Benzodiazepines (BZDs) and related drugs (Z-drugs) are mainly taken chronically, and older people are much more likely to take them on a chronic basis despite recommendations. Withdrawal symptoms could be an obstacle to stopping BZD/Z-drug administration. The main objective of this study is to estimate the prevalence of withdrawal symptoms in patients aged 65 years and older who have experience a stop of BZD/Z-drug. The secondary objectives are to describe the withdrawal symptoms and identify factors associated.
Method
This ancillary study was based on a national observational study in patients with chronic BZD/Z-drug consumption. Patients who made at least one BZD/Z-drug stop experience were selected. Withdrawal symptoms are described, and a logistic regression was carried out to identify the variables most associated with withdrawal symptoms.
Results
In total, 697 patients were selected: 78% experienced at least one withdrawal symptom after a stop administering BZDs or Z-drugs; most of the withdrawal symptoms were psychological disorders.
Conclusion
Our study identifies a specific population experiencing withdrawal symptoms and who cannot stop administering BZD/Z-drug. We assume that withdrawal symptoms in patients with chronic use play an essential role in the nonstop use of BZD/Z-drugs.</description><subject>Antidepressants</subject><subject>Benzodiazepines</subject><subject>Biomedical and Life Sciences</subject><subject>Biomedicine</subject><subject>Clinical Trial</subject><subject>Drug withdrawal</subject><subject>Drugs</subject><subject>Life Sciences</subject><subject>Older people</subject><subject>Pharmacology/Toxicology</subject><subject>Population studies</subject><subject>Withdrawal</subject><issn>0031-6970</issn><issn>1432-1041</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNp9kU9r3DAQxUVpaLZpvkAPRdBLCnE7-rO2lUtIQ5sEFnppz0KWZmMtXtmRvLs0n77aOEkhh5wG3vzmzQyPkI8MvjKA6lsC4LwugEMBIgtF9YbMmBS8YCDZWzIDEKwoVQWH5H1KKwA2VyDekUOR8bLk5YysvmO475039zj4gHTnx9ZFszMd9YH2ncNIB-yHDs_orjUj9YmOLdIh4tZ0GCyeTrqJ-NBI_jakU2qCy7q3LR3M6DGM6fwDOViaLuHxYz0if37--H15XSx-Xd1cXiwKK0GNhRONaoyxS6eUnTOeLwblLDT5MSmM5Kq2DktmmHXzKsulxVrOOciqEUIqcUS-TL6t6fQQ_drEv7o3Xl9fLPReg2wkmZBbltmTiR1if7fBNOq1Txa7zgTsN0lnsJaZ53VGP79AV_0mhvxJpqoKFDCoMsUnysY-pYjL5wsY6H1qekpN59T0Q2p6P_Tp0XrTrNE9jzzFlAExASm3wi3G_7tfsf0Hz8ugRw</recordid><startdate>20210201</startdate><enddate>20210201</enddate><creator>Jobert, Alexandra</creator><creator>Laforgue, Edouard-Jules</creator><creator>Grall-Bronnec, Marie</creator><creator>Rousselet, Morgane</creator><creator>Péré, Morgane</creator><creator>Jolliet, Pascale</creator><creator>Feuillet, Fanny</creator><creator>Victorri-Vigneau, Caroline</creator><general>Springer Berlin Heidelberg</general><general>Springer Nature B.V</general><general>Springer Verlag</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7TK</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>H94</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>M1P</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>1XC</scope><orcidid>https://orcid.org/0000-0001-9117-0934</orcidid><orcidid>https://orcid.org/0000-0003-0722-7243</orcidid><orcidid>https://orcid.org/0000-0003-0191-9249</orcidid><orcidid>https://orcid.org/0000-0002-7400-1212</orcidid><orcidid>https://orcid.org/0000-0002-3745-2532</orcidid><orcidid>https://orcid.org/0000-0001-5804-5269</orcidid><orcidid>https://orcid.org/0000-0003-4027-7963</orcidid></search><sort><creationdate>20210201</creationdate><title>Benzodiazepine withdrawal in older people: what is the prevalence, what are the signs, and which patients?</title><author>Jobert, Alexandra ; Laforgue, Edouard-Jules ; Grall-Bronnec, Marie ; Rousselet, Morgane ; Péré, Morgane ; Jolliet, Pascale ; Feuillet, Fanny ; Victorri-Vigneau, Caroline</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c409t-d3b9baacfd99c51290309dc0b43243a4298cde61a1cd570b46ce8452047b33493</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Antidepressants</topic><topic>Benzodiazepines</topic><topic>Biomedical and Life Sciences</topic><topic>Biomedicine</topic><topic>Clinical Trial</topic><topic>Drug withdrawal</topic><topic>Drugs</topic><topic>Life Sciences</topic><topic>Older people</topic><topic>Pharmacology/Toxicology</topic><topic>Population studies</topic><topic>Withdrawal</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Jobert, Alexandra</creatorcontrib><creatorcontrib>Laforgue, Edouard-Jules</creatorcontrib><creatorcontrib>Grall-Bronnec, Marie</creatorcontrib><creatorcontrib>Rousselet, Morgane</creatorcontrib><creatorcontrib>Péré, Morgane</creatorcontrib><creatorcontrib>Jolliet, Pascale</creatorcontrib><creatorcontrib>Feuillet, Fanny</creatorcontrib><creatorcontrib>Victorri-Vigneau, Caroline</creatorcontrib><creatorcontrib>FAN-Network</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing & Allied Health Database</collection><collection>Neurosciences Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>Hyper Article en Ligne (HAL)</collection><jtitle>European journal of clinical pharmacology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Jobert, Alexandra</au><au>Laforgue, Edouard-Jules</au><au>Grall-Bronnec, Marie</au><au>Rousselet, Morgane</au><au>Péré, Morgane</au><au>Jolliet, Pascale</au><au>Feuillet, Fanny</au><au>Victorri-Vigneau, Caroline</au><aucorp>FAN-Network</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Benzodiazepine withdrawal in older people: what is the prevalence, what are the signs, and which patients?</atitle><jtitle>European journal of clinical pharmacology</jtitle><stitle>Eur J Clin Pharmacol</stitle><addtitle>Eur J Clin Pharmacol</addtitle><date>2021-02-01</date><risdate>2021</risdate><volume>77</volume><issue>2</issue><spage>171</spage><epage>177</epage><pages>171-177</pages><issn>0031-6970</issn><eissn>1432-1041</eissn><abstract>Purpose
Benzodiazepines (BZDs) and related drugs (Z-drugs) are mainly taken chronically, and older people are much more likely to take them on a chronic basis despite recommendations. Withdrawal symptoms could be an obstacle to stopping BZD/Z-drug administration. The main objective of this study is to estimate the prevalence of withdrawal symptoms in patients aged 65 years and older who have experience a stop of BZD/Z-drug. The secondary objectives are to describe the withdrawal symptoms and identify factors associated.
Method
This ancillary study was based on a national observational study in patients with chronic BZD/Z-drug consumption. Patients who made at least one BZD/Z-drug stop experience were selected. Withdrawal symptoms are described, and a logistic regression was carried out to identify the variables most associated with withdrawal symptoms.
Results
In total, 697 patients were selected: 78% experienced at least one withdrawal symptom after a stop administering BZDs or Z-drugs; most of the withdrawal symptoms were psychological disorders.
Conclusion
Our study identifies a specific population experiencing withdrawal symptoms and who cannot stop administering BZD/Z-drug. We assume that withdrawal symptoms in patients with chronic use play an essential role in the nonstop use of BZD/Z-drugs.</abstract><cop>Berlin/Heidelberg</cop><pub>Springer Berlin Heidelberg</pub><pmid>33006626</pmid><doi>10.1007/s00228-020-03007-7</doi><tpages>7</tpages><orcidid>https://orcid.org/0000-0001-9117-0934</orcidid><orcidid>https://orcid.org/0000-0003-0722-7243</orcidid><orcidid>https://orcid.org/0000-0003-0191-9249</orcidid><orcidid>https://orcid.org/0000-0002-7400-1212</orcidid><orcidid>https://orcid.org/0000-0002-3745-2532</orcidid><orcidid>https://orcid.org/0000-0001-5804-5269</orcidid><orcidid>https://orcid.org/0000-0003-4027-7963</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0031-6970 |
| ispartof | European journal of clinical pharmacology, 2021-02, Vol.77 (2), p.171-177 |
| issn | 0031-6970 1432-1041 |
| language | eng |
| recordid | cdi_hal_primary_oai_HAL_hal_03244134v1 |
| source | SpringerLink Journals |
| subjects | Antidepressants Benzodiazepines Biomedical and Life Sciences Biomedicine Clinical Trial Drug withdrawal Drugs Life Sciences Older people Pharmacology/Toxicology Population studies Withdrawal |
| title | Benzodiazepine withdrawal in older people: what is the prevalence, what are the signs, and which patients? |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-20T01%3A34%3A24IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_hal_p&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Benzodiazepine%20withdrawal%20in%20older%20people:%20what%20is%20the%20prevalence,%20what%20are%20the%20signs,%20and%20which%20patients?&rft.jtitle=European%20journal%20of%20clinical%20pharmacology&rft.au=Jobert,%20Alexandra&rft.aucorp=FAN-Network&rft.date=2021-02-01&rft.volume=77&rft.issue=2&rft.spage=171&rft.epage=177&rft.pages=171-177&rft.issn=0031-6970&rft.eissn=1432-1041&rft_id=info:doi/10.1007/s00228-020-03007-7&rft_dat=%3Cproquest_hal_p%3E2448403228%3C/proquest_hal_p%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2477090107&rft_id=info:pmid/33006626&rfr_iscdi=true |